HCSGD entry for PLK1
1. General information
| Official gene symbol | PLK1 |
|---|---|
| Entrez ID | 5347 |
| Gene full name | polo-like kinase 1 |
| Other gene symbols | PLK STPK13 |
| Links to Entrez Gene | Links to Entrez Gene |
2. Neighbors in the network
This gene isn't in Literature mining network.
3. Gene ontology annotation
GO ID | GO term | Evidence | Category |
|---|---|---|---|
| GO:0000070 | Mitotic sister chromatid segregation | IMP | biological_process |
| GO:0000086 | G2/M transition of mitotic cell cycle | IDA TAS | biological_process |
| GO:0000122 | Negative regulation of transcription from RNA polymerase II promoter | IMP | biological_process |
| GO:0000278 | Mitotic cell cycle | TAS | biological_process |
| GO:0000281 | Mitotic cytokinesis | IDA | biological_process |
| GO:0000776 | Kinetochore | IDA | cellular_component |
| GO:0000910 | Cytokinesis | IDA IMP | biological_process |
| GO:0000922 | Spindle pole | IDA IEA | cellular_component |
| GO:0000942 | Condensed nuclear chromosome outer kinetochore | IDA | cellular_component |
| GO:0001578 | Microtubule bundle formation | IDA | biological_process |
| GO:0004672 | Protein kinase activity | IDA IEA | molecular_function |
| GO:0004674 | Protein serine/threonine kinase activity | IDA IMP | molecular_function |
| GO:0005515 | Protein binding | IPI | molecular_function |
| GO:0005524 | ATP binding | IEA | molecular_function |
| GO:0005634 | Nucleus | IDA | cellular_component |
| GO:0005654 | Nucleoplasm | TAS | cellular_component |
| GO:0005737 | Cytoplasm | IEA | cellular_component |
| GO:0005813 | Centrosome | IDA | cellular_component |
| GO:0005819 | Spindle | IDA | cellular_component |
| GO:0005829 | Cytosol | TAS | cellular_component |
| GO:0005876 | Spindle microtubule | IDA | cellular_component |
| GO:0006468 | Protein phosphorylation | IDA | biological_process |
| GO:0007067 | Mitosis | IDA IMP | biological_process |
| GO:0007077 | Mitotic nuclear envelope disassembly | TAS | biological_process |
| GO:0007091 | Metaphase/anaphase transition of mitotic cell cycle | TAS | biological_process |
| GO:0007092 | Activation of mitotic anaphase-promoting complex activity | IDA | biological_process |
| GO:0007094 | Mitotic spindle assembly checkpoint | IMP | biological_process |
| GO:0007346 | Regulation of mitotic cell cycle | IMP | biological_process |
| GO:0008017 | Microtubule binding | IDA | molecular_function |
| GO:0008283 | Cell proliferation | TAS | biological_process |
| GO:0010800 | Positive regulation of peptidyl-threonine phosphorylation | IMP | biological_process |
| GO:0010997 | Anaphase-promoting complex binding | IPI | molecular_function |
| GO:0016301 | Kinase activity | TAS | molecular_function |
| GO:0016567 | Protein ubiquitination | IDA | biological_process |
| GO:0018105 | Peptidyl-serine phosphorylation | IDA | biological_process |
| GO:0019901 | Protein kinase binding | IPI | molecular_function |
| GO:0030071 | Regulation of mitotic metaphase/anaphase transition | IMP | biological_process |
| GO:0030496 | Midbody | IDA | cellular_component |
| GO:0031145 | Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process | TAS | biological_process |
| GO:0031572 | G2 DNA damage checkpoint | IDA | biological_process |
| GO:0031648 | Protein destabilization | IDA | biological_process |
| GO:0032436 | Positive regulation of proteasomal ubiquitin-dependent protein catabolic process | IMP | biological_process |
| GO:0040038 | Polar body extrusion after meiotic divisions | IEA | biological_process |
| GO:0043066 | Negative regulation of apoptotic process | IMP | biological_process |
| GO:0043393 | Regulation of protein binding | IMP | biological_process |
| GO:0045736 | Negative regulation of cyclin-dependent protein serine/threonine kinase activity | IMP | biological_process |
| GO:0045862 | Positive regulation of proteolysis | IDA | biological_process |
| GO:0046677 | Response to antibiotic | IEA | biological_process |
| GO:0051233 | Spindle midzone | IDA IEA | cellular_component |
| GO:0051297 | Centrosome organization | IMP | biological_process |
| GO:0051437 | Positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle | TAS | biological_process |
| GO:0051439 | Regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle | TAS | biological_process |
| GO:0051443 | Positive regulation of ubiquitin-protein ligase activity | IMP | biological_process |
| GO:0051726 | Regulation of cell cycle | TAS | biological_process |
| GO:0071168 | Protein localization to chromatin | IDA | biological_process |
Entries Per Page
Displaying Page of
4. Expression levels in datasets
- Meta-analysis result
| p-value up | p-value down | FDR up | FDR down |
|---|---|---|---|
| 0.9423049390 | 0.0000868964 | 0.9999902473 | 0.0160272727 |
- Individual experiment result
( "-" represent NA in the specific microarray platform )
( "-" represent NA in the specific microarray platform )
| Data source | Up or down | Log fold change |
|---|---|---|
| GSE11954 | Down | -0.4936636012 |
| GSE13712_SHEAR | Down | -0.2891348181 |
| GSE13712_STATIC | Down | -0.5000955133 |
| GSE19018 | Up | 0.0837628463 |
| GSE19899_A1 | Down | -0.9748950433 |
| GSE19899_A2 | Down | -2.4370220152 |
| PubMed_21979375_A1 | Down | -1.3912510510 |
| PubMed_21979375_A2 | Down | -3.5507997491 |
| GSE35957 | Down | -2.0278946532 |
| GSE36640 | Down | -1.8940889238 |
| GSE54402 | Down | -0.4379923916 |
| GSE9593 | Down | -1.6522397781 |
| GSE43922 | Down | -3.0908303388 |
| GSE24585 | Down | -0.2951698161 |
| GSE37065 | Down | -1.4684149513 |
| GSE28863_A1 | Down | -0.2896954027 |
| GSE28863_A2 | Up | 0.7105959965 |
| GSE28863_A3 | Down | -0.1256935704 |
| GSE28863_A4 | Up | 0.5000067651 |
| GSE48662 | Down | -0.5894538113 |
5. Regulation relationships with compounds/drugs/microRNAs
- Compounds
Entries Per Page
Displaying Page of
- Drugs
Name | Drug | Accession number |
|---|---|---|
| 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol | DB06897 | - |
| 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide | DB06963 | - |
| 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE | DB07186 | - |
| 1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea | DB07789 | - |
| (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE | DB08059 | - |
- MicroRNAs
- mirTarBase
MiRNA_name | mirBase ID | miRTarBase ID | Experiment | Support type | References (Pubmed ID) |
|---|---|---|---|---|---|
| hsa-miR-100-5p | MIMAT0000098 | MIRT000382 | Luciferase reporter assay//qRT-PCR | Functional MTI | 19739117 |
| hsa-miR-100-5p | MIMAT0000098 | MIRT000382 | Luciferase reporter assay//qRT-PCR//Western blot | Functional MTI | 22120675 |
| hsa-miR-16-5p | MIMAT0000069 | MIRT001430 | pSILAC//Proteomics;Other | Functional MTI (Weak) | 18668040 |
| hsa-miR-155-5p | MIMAT0000646 | MIRT020615 | Proteomics | Functional MTI (Weak) | 18668040 |
| hsa-miR-877-5p | MIMAT0004949 | MIRT037217 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-874-3p | MIMAT0004911 | MIRT037761 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-92a-1-5p | MIMAT0004507 | MIRT038920 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-let-7b-5p | MIMAT0000063 | MIRT051975 | CLASH | Functional MTI (Weak) | 23622248 |
Entries Per Page
Displaying Page of
- mirRecord
MicroRNA name | mirBase ID | Target site number | MiRNA mature ID | Test method inter | MiRNA regulation site | Reporter target site | Pubmed ID |
|---|---|---|---|---|---|---|---|
| hsa-miR-100-5p | MIMAT0000098 | 1 | hsa-miR-100 | 19739117 |
Entries Per Page
Displaying Page of
6. Text-mining results about the gene
Gene occurances in abstracts of cellular senescence-associated articles: 9 abstracts the gene occurs.
PubMed ID of the article | Sentenece the gene occurs |
|---|---|
| 26794530 | Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel |
| 26794530 | Polo-like kinase 1 (PLK1), a serine/threonine kinase and an oncogene, is crucial in regulating cell cycle progression |
| 26794530 | PLK1 also has been demonstrated as a potential target of osteosarcoma (OS) by using short hairpin RNA libraries in lentiviral vectors for screening of protein kinase |
| 26794530 | In preclinical studies, GSK461364, a potent and selective ATP-competitive PLK1 inhibitor, showed antiproliferative activity against multiple tumor cell lines |
| 26794530 | In the present study, we evaluated the expression level of PLK1 in OS and explored the cytotoxic mechanism of GSK461364 against OS |
| 26794530 | PLK1 was significantly overexpressed in OS compared with normal osteoblasts and other types of sarcoma |
| 26794530 | GSK461364 inhibited PLK1 and caused mitotic arrest by inducing G2/M arrest in OS cells |
| 26794530 | In conclusion, the present study revealed that PLK1 was overexpressed in OS and that GSK461364 exerted its cytotoxic effect on OS by inducing mitotic arrest and subsequent apoptosis and induced cellular senescence; therefore, senescence-associated markers can be used as treatment biomarkers, and a combination of GSK461364 and paclitaxel can potentially treat OS |
| 25505268 | PLK1 inhibition down-regulates polycomb group protein BMI1 via modulation of the miR-200c/141 cluster |
| 25505268 | Here, we report that the polo-like kinase 1 (PLK1) regulates BMI1 expression, and that its inhibition can efficiently down-regulate BMI1 expression and PRC1 activity, and induce premature senescence in breast cancer cells |
| 25505268 | We also show that the exogenous BMI1 overexpression mitigates anti-oncogenic effects of PLK1 inhibition and overcomes senescence induction by PLK1 inhibitors |
| 25505268 | We further show that PLK1 inhibition down-regulates BMI1 by upregulating the miRNA-200c/141 cluster, which encodes miR-200c and miR-141, both of which are known to post-transcriptionally downregulate BMI1 expression |
| 25505268 | Thus, our data suggest that PLK1 inhibitors can be successfully used to inhibit growth of tumors in which PcG protein BMI1 is overexpressed or the PRC1 activity is deregulated |
| 25365521 | Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines |
| 25365521 | Plk1 is a checkpoint protein whose role spans all of mitosis and includes DNA repair, and is highly conserved in eukaryotes from yeast to man |
| 25365521 | Consistent with this wide array of functions for Plk1, the cellular consequences of Plk1 disruption are diverse, spanning delays in mitotic entry, mitotic spindle abnormalities, and transient mitotic arrest leading to mitotic slippage and failures in cytokinesis |
| 25365521 | In this work, we present the in vitro and in vivo consequences of Plk1 inhibition in cancer cells using potent, selective small-molecule Plk1 inhibitors and Plk1 genetic knock-down approaches |
| 25365521 | We demonstrate for the first time that cellular senescence is the predominant outcome of Plk1 inhibition in some cancer cell lines, whereas in other cancer cell lines the dominant outcome appears to be apoptosis, as has been reported in the literature |
| 25365521 | Taken together, our findings expand the view of Plk1 inhibition, demonstrating the occurrence of a non-apoptotic outcome in some settings |
| 25365521 | Our findings are also consistent with the possibility that mitotic arrest observed as a result of Plk1 inhibition is at least partially due to the presence of unrepaired double-strand breaks in mitosis |
| 25365521 | These novel findings may lead to alternative strategies for the development of novel therapeutic agents targeting Plk1, in the selection of biomarkers, patient populations, combination partners and dosing regimens |
| 24989836 | A previous study from our group indicated that mitotic checkpoint kinases such as PLK1 and Aurora A are downregulated by HDACIs |
| 24879067 | Unlike differentiated cells, glioma stem cells responded to moderate Aurora A inhibition with spindle defects, polyploidization and a dramatic increase in cellular senescence, and were selectively sensitive to Aurora A and Plk1 inhibitor treatment |
| 23907611 | In contrast, expression of Plk1, an upstream regulator of the cyclin B1/Cdk1 complex, or FoxM1 (forkhead box M1), a master transcriptional factor for the cell cycle regulators of G2/M phase, restored the cell cycle in these cells |
| 23525475 | Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway |
| 23525475 | Polo-like kinase 1 (PLK1) plays a key role in various stages of mitosis from entry into M phase to exit from mitosis |
| 23525475 | We found that expression of PLK1 decreased in human dermal fibroblasts and human umbilical vein endothelial cells under replicative senescence and premature senescence induced by adriamycin |
| 23525475 | PLK1 knockdown with PLK1 small interfering RNAs in young cells induced premature senescence |
| 23525475 | In contrast, upregulation of PLK1 in old cells partially reversed senescence phenotypes |
| 23525475 | Cellular senescence by PLK1 inhibition was observed in p16 knockdown cells but not in p53 knockdown cells |
| 23525475 | Our data suggest that PLK1 repression might result in cellular senescence in human primary cells via a p53-dependent pathway |
| 21241890 | Importantly, we demonstrate that PTEN mutant and PTEN null states are not synonymous as they are differentially sensitive to pharmacological inhibition of APC-CDH1 targets such as PLK1 and Aurora kinases |
| 21113463 | Cell transfection with anti-E6 and anti-E7 short interfering RNA moderately reduced the expression of mRNA for CDC25C, GRB2, GTSE1, and PLK1 genes and induced expression of CDKN1A (p21(CIP)) gene mRNA |
Entries Per Page
Displaying Page of
